anrukinzumab (IMA-638) - Pfizer
Pfizer pipeline (Pfizer Press Release) - Mar 1, 2014 - Anrukinzumab: Discontinued from development for ulcerative colitis. 
Discontinued • Immunology • Inflammatory Bowel Disease
http://www.pfizer.com/sites/default/files/product-pipeline/BT_February%2028%2C%202014%20Pipeline%20Update_28Feb14.pdf
 
Mar 1, 2014
 
.